
MedTech & Digital Health


AiSee
Unlocking Your Potential
Put on AiSee - the world's first conversational visual intelligence. With AiSee, every aisle, every street, every moment is yours to explore
AiSee’s Visual Intelligence Platform delivers real-time visual understanding and personalised smart assistance. It processes natural language commands, learns user preferences, and performs tasks using multimodal tools. Hardware-agnostic and adaptable, AiSee runs seamlessly on phones, compatible smart glasses, and the AiSee headset—turning any device into a seeing, thinking companion.
- Full-stack intelligence from perception to conversation - holistic AI assistant
- Hardware-agnostic platform easily scalable for consumer or enterprise use
- Site-specific intelligence and personalized assistance across environments
- Singapore AI assistive tech market for visual impairment valued at US$20M (SOM)
- Scalable Visual Intelligence Platform extendable to domains like eldercare
- Addresses broader global market projected to reach US$208.6 billion by 2032

Vanessa Tang
CEO

Prof Suranga Nanayakkara
Non-Executive Director

Kian Peen Yeo
Director

Hussel Suriyaarachchi
CTO

Debashish Pal
Venture Architect


ArcVance
Separation: Detection: Clarity
Offer advanced blood processing to empower sensitive cancer detection by removing cellular contamination and boosting cancer biomarker signals
An automated microfluidic platform for point-of-care plasma isolation, removing fast degrading blood cells to protect plasma cancer cell-free DNA/RNA biomarkers from cellular contamination
- 1x cleaner plasma and more portable than conventional centrifuge
- Achieve 90% sensitivity in pilot lung cancer study with cell-free RNA biomarkers
- Global liquid biopsy (cancer blood test) market: US$5B, CAGR 25%
- More than 10% cancer patients are misdiagnosed annually, creating US$26B additional burden to the healthcare system

Dr Leong Sheng Yuan
CEO

Patrick Chua Siew Eng
Chief Commercialization Officer

Dr Hou Han Wei
Scientific Co-founder

Lok Wan Wei
Lead Engineer

Jarrell Woo Wei Cheng
Senior Engineer

Ashwin Chari
Venture Builder

Assoc Professor Ali Asgar Bhagat
Commercial Champion


CeruClean
The effortless way to keep your hearing aids with perfect sound, clean, and hygienic
Restores sound clarity for hearing aid users with clinical-grade, effortless home cleaning that saves up to US$300 annually
A Plug-and-play, clinical-grade device that deeply cleans hearing aid receivers at home using patented fluid, UV-C, and drying cycles
- Deep inside-out cleaning -Single-use, hygienic fluid cartridges
- Dual-cycle & elder-friendly design
- 52 million hearing aid users globally suffer from earwax-related sound degradation
- US$7.6B global market, with US$1.2M projected revenue from Southwest Delhi in 3 years - 60-70% of hearing aid failures due to wax buildup cost users US$150-$300 annually

Dr Zaher Judeh
CEO

Nishtha Thakur
Technology Lead

Carrie-Ann Lee
Business Lead

Ashwin Chari
Venture Builder

Sherry Wang
Commercial Champion


ChemT Biotechnology
AI small molecules for high-yield biologics manufacturing
AI-designed small molecules that precisely modulate CHO and T cells to boost biologics yield and consistency
CelMo platform discovers cell-modulating molecules 24× faster. Chemplify boosts cell yields 5–10×, improving quality and cutting costs by 30–40%
- First mover in AI-driven cellular drug design (“drugs for cells”)
- Biology-first approach enabling tunable cell enhancement
- Building an AI Virtual Cell trained on 10B+ omics reads for predictive design, not trial-and-error
- Global biologics manufacturing market projected to reach >$600B by 2030
- Current processes are inefficient, with up to 40% production loss due to cellular variability
- Chemplify improves yield 5–10× while reducing manufacturing cost by 30–40%

Jie Sun
Co-Founder & CEO

Dr Ling Wu
President & Co-founder

Prof Nicholas Gascoigne
Scientific Advisor & Co-founder

Debashish Pal
Venture Architect

James Hsieh
Commercial Champion


Liminal Analytix
Transforming ophthalmic drug development with disease-specific, high-performance preclinical in vitro toxicology testing
Addresses the significant challenge in ophthalmic drug development: the need for reliable, efficient, and ethical toxicity testing during early-stage formulation development
OcuDot is a fully functional, cell-free in vitro ocular toxicity testing assay designed for upstream ophthalmic drug development. It directly addresses the most urgent pain points of beachhead customers — the need for rapid, predictive, and ethical preclinical toxicity screening tool that avoids the high cost, delay, and limitations of animal models
- Clear advantage in customisation and turnaround time
- Superior cost effectiveness compared to competitors
- Ability to differentiate same-category eye irritants
- US$1B TAM, consisting of over 4,000 potential customers globally
- Our SAM is the Research Use Only (RUO) market, which is over US$0.5B and comprised of 2000 potential customers

Dr James Ho Chin Shing
CEO

Dr Chanel Yee Kitmon
CSO

Dr Yeo Yee Phan
CTO

Kum Siau Ling
COO

Edward Ng
Venture Builder

Stefan Bahnmueller
Commercial Champion


Sentinan
Advanced digital auscultation with AI-powered insights
Sentinan gives patients, caregivers and clinicians instant, explainable AI on heart & lung sounds, enabling earlier detection even in remote or noisy settings
Handheld digital stethoscope streams and records auscultation audio; cloud AI detects murmurs & lung anomalies in seconds, shows visual explanations, and syncs with EMRs or telehealth apps
- Digital stethoscope with explainable AI that clinicians trust
- Designed for non-clinicians with portable use for telehealth screening -SEA-trained data with local partners and faster regulatory paths
- Cardiovascular and respiratory diseases are global #1 and #3 causes of death
- SEA telehealth market: US$8.07B (2024) to US$21.8B by 2030
- Global digital stethoscope market forecast to reach US$539.6M by 2034

Dr Ho Chin Keong
CEO

Terry Zhao
CTO

Ray Chan
COO

Saw Biing Huei
Venture Architect